Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A | P04350 | 1/20 | 0.52 |
| ▸ | TUBB | P07437 | 1/20 | 0.52 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.52 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.52 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.52 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.52 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.52 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.52 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.52 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.52 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.52 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.52 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.52 |
| ▸ | TUBB2B | Q9BVA1 | 1/20 | 0.52 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7619968 | 0.87 | ACHE (0.56) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL21980854 | 0.84 | PTGS2 (0.47) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Bromide SCHEMBL28463593 | 0.83 | PTGS2 (0.46) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL8994697 | 0.80 | TDP1 (0.48) | CYP3A4TDP1MEN1MAPK1KMT2A | |
| SCHEMBL1042656 | 0.78 | TUBB4A (0.42) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Hydrochloric Acid SCHEMBL11656824 | 0.77 | TDP1 (0.44) | CYP3A4TDP1MAPTMEN1MAPK1 | |
| Methane SCHEMBL660326 | 0.77 | CYP3A4 (0.40) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL19019980 | 0.76 | TNFRSF1A (0.46) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Methoxymethane SCHEMBL9622762 | 0.75 | CYP3A4 (0.75) | CYP3A4TDP1MAPK1SMN1; SMN2ACHE | |
| SCHEMBL17829472 | 0.74 | TDP1 (0.46) | CYP3A4TDP1MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1341797-A4 | ORTHO SUBSTITUTED CHIRAL PHOSPHINES AND PHOSPHINITES AND THEIR USE IN ASYMMETRIC CATAYLTIC REACTIONS | PENN STATE RES FOUND (US) | 2005-06-15 | — | — | EP | disclosed |
| US-6855657-B2 | Ortho substituted chiral phosphines and phosphinites and their use in asymmetric catalytic reactions | THE PENN STATE RESEARCH FOUNDATION (US) | 2005-02-15 | — | — | US | disclosed |
| US-20040068126-A1 | Ortho substituted chiral phosphines and phosphinites and their use in asymmetric catalytic reactions | THE PENN STATE RESEARCH FOUNDATION | 2004-04-08 | — | — | US | disclosed |
| US-6653485-B2 | Particularly effective in Ru-catalyzed asymmetric hydrogenation of beta-ketoesters to beta-hydroxyesters and ruthenium-catalyzed asymmetric hydrogenation of enamides to beta amino acids; catalyst selectivity | THE PENN STATE RESEARCH FOUNDATION | 2003-11-25 | — | — | US | disclosed |
| EP-1341797-A1 | ORTHO SUBSTITUTED CHIRAL PHOSPHINES AND PHOSPHINITES AND THEIR USE IN ASYMMETRIC CATAYLTIC REACTIONS | THE PENN STATE RESEARCH FOUNDATION (US) | 2003-09-10 | — | — | EP | disclosed |
| US-20020128501-A1 | Particularly effective in Ru-catalyzed asymmetric hydrogenation of beta-ketoesters to beta-hydroxyesters and ruthenium-catalyzed asymmetric hydrogenation of enamides to beta amino acids; catalyst selectivity | THE PENN STATE RESEARCH FOUNDATION | 2002-09-12 | — | — | US | disclosed |
| WO-2002040491-A1 | ORTHO SUBSTITUTED CHIRAL PHOSPHINES AND PHOSPHINITES AND THEIR USE IN ASYMMETRIC CATAYLTIC REACTIONS | THE PENN STATE RESEARCH FOUNDATION (US) | 2002-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040068126-A1 | Ortho substituted chiral phosphines and phosphinites and their use in asymmetric catalytic reactions | BCKDK, PDK3, HCK | TUBB4A 3594/4885TUBB 3112/4885TUBA3C 3814/4885 |
| US-20020128501-A1 | Particularly effective in Ru-catalyzed asymmetric hydrogenation of beta-ketoesters to beta-hydroxyesters and ruthenium-catalyzed asymmetric hydrogenation of enamides to beta amino acids; catalyst selectivity | HRH4, BCKDK, HRH3 | TUBB4A 3655/4885TUBB 3045/4885TUBA3C 3738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.